title: [Benzylthiouracil induced ANCA-positive vasculitis: study of three cases and review of the literature].
abstract: BACKGROUND
  Vasculitis with antineutrophilic cytoplasmic antibodies (ANCA) have been reported in patients treated with anti-thyroid drugs, especially propylthiouracil. Benzylthiouracil, which exhibits similar structural likeness with propylthiouracil, has been recently observed to be associated with Anca-positive vasculitis.
  
  
  METHODS
  We present a study of three women with Grave's disease aged 21, 37 and 40 years, who were treated with benzylthiouracil. These patients developed vasculitis characterized by constitutional symptoms (two patients), joint pain (two patients), renal involvement (two patients), pulmonary hemorrhage (one patient) and multiple neuropathy (one patient). All patients presented p-ANCA with anti-MPO pattern. Discontinuation of benzylthiouracil and treatment with corticosteroids improved systemic involvement in all patients.
  
  
  CONCLUSIONS
  Much like other anti-thyroid drugs, benzylthiouracil can be associated with ANCA-positive vasculitis. Because of the gravity of this complication, clinical monitoring is recommended in patients taking benzylthiouracil. If vasculitis develops, the anti-thyroid drug should be discontinued and corticosteroid treatment, with immunosuppressors in some cases, is initiated.
authors.affiliation: Service de Médecine Interne, CHU Hédi Chaker, Sfax, Tunisie. friguimakram@yahoo.fr
authors.forename: M
authors.initials: M
authors.lastname: Frigui
authors.forename: M
authors.initials: M
authors.lastname: Kechaou
authors.forename: S
authors.initials: S
authors.lastname: Haddouk
authors.forename: A
authors.initials: A
authors.lastname: Masmoudi
authors.forename: N
authors.initials: N
authors.lastname: Kaddour
authors.forename: H
authors.initials: H
authors.lastname: Masmoudi
authors.forename: H
authors.initials: H
authors.lastname: Turki
authors.forename: Z
authors.initials: Z
authors.lastname: Bahloul
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000906:Antibodies / Q000032:analysis; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis / Q000276:immunology*; D013956:Antithyroid Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006111:Graves Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009192:Myelography; D009195:Peroxidase / Q000276:immunology / Q000378:metabolism; D013889:Thiouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014657:Vasculitis / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology*; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000906:Antibodies; D019268:Antibodies, Antineutrophil Cytoplasmic; D013956:Antithyroid Agents; D007166:Immunosuppressive Agents; D013889:Thiouracil; D009195:Peroxidase; C019269:benzylthiouracil